Throughout the course of the past eighteen months, the CRI has gruellingly been working to bring cannabis analytical capabilities up to Department of Health and the South African Health Products Regulatory Authority (SAHPRA) regulations to meet the Section 22C (1)(b) and Section 22D in together with Regulation 23 and 24 of the Medicines and Related Substance Act of 1965 license standards. 
It allows participants in the cannabis industry to cultivate cannabis and cannabis resins, extract and test various forms of cannabis, manufacture cannabis containing medicine as well as import, export and distribute cannabis containing medicines within the parameters of the SAHPRA and the International Narcotic Controls Board (INCB).
A review of alternative research shows that more data is required in order to establish exactly how cannabis use ties in with general public health.
Information was reviewed based on the following:
1. Lifetime cannabis use
2. Age of first use
3. How often and where the use took place
4. Method of consumption
5. Source for cannabis
6. Reasons for using and type of cannabis
7. Overall opinions on cannabis
This would prove to be a challenge for health providers as researching and monitoring is significant for variation in data availability related to cannabis use including behaviours and perceptions and the availability of pre-legalisation versus post-legalisation data.

In addition to showing gaps in existing research, the idea behind compiling these surveys was to put all the information in one place so that researchers, cannabis legislators, and other interested parties can access it all at once and also see what does and doesn’t work. The surveys that included more than just yes-or-no questions provided more information, and the hope is that more in-depth survey methods will be used going forward. The most basic of these indicators in thinking about cannabis legalisation is how much do people use cannabis and are people changing the way in which they use it – are they using more edibles versus smoking it? Are there changes in how often they’re using it? And one thing that’s important from a public health perspective, who is using and how is that changing? For example, are adolescents using cannabis more frequently?
Surveys can also be altered and updated as part of this ongoing study, which can prove very helpful when looking to compare pre and post-legalisation data. Although this compiled research reveals that a lot more work needs to be done, it also provides a very helpful tool for future purposes.
Furthermore, development of addition research with a wide-ranging body of unbiased candidates are required to support studies and research on:
  1. Product packaging, including consumer awareness and comprehension of warning labels and consumption advice.

  2. Consumer perceptions of cannabis-related risk, such as the risk associated with driving while under the influence of cannabis.

  3. The overall influence of advertising on consumption, including openness to use among youth.

  4. Apprehensions to change to the regulated market, such as the updated influence of the price and the density of legalised outlets.

  5. Chemical analysis of cannabis products, including errors in labelled and actual quantity of CBD; and potential chemical conversion of cannabis in certain environments.

  6. The chemical stability of cannabis products in various storage features.
  7. Pharmacology of cannabinoids, such as the cannabis genetic features associated with substance use disorder.

  8. Safe consumption and safe storage messages for adults, including parents and tourists.

  9. Guidance for consumers who are pregnant or breastfeeding.